Research analysts at HC Wainwright cut their Q1 2025 earnings estimates for Axsome Therapeutics in a research report issued ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price increased by equities research analysts at HC ...

Q4 2024 Earnings Call Transcript February 18, 2025 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% ...

Shares of Axsome Therapeutics ( AXSM -0.40%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Halozyme (HALO – Research Report), Walgreens Boots Alliance ...

RBC Capital raised the firm’s price target on Axsome Therapeutics (AXSM) to $192 from $143 and keeps an Outperform rating on the shares after ...

Axsome Therapeutics reports 66% Q4 revenue growth, blockbuster potential for Auvelity, and robust pipeline progress with 3 NDA filings and key ...

Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.